Showing 4831-4840 of 7936 results for "".
- DermSpectra Releases Total Body Digital Skin Imaging Systemhttps://practicaldermatology.com/news/dermspectra-releases-its-total-body-digital-skin-imaging-system/2459052/DermSpectra realease its DermSpectra Total Body Digital Skin Imaging System, which enables physicians to monitor critical skin changes (skin cancers, eczema, lesions, psoriasis, and rashes) over time. The DermSpectra advanced medical technology allows physicians to digitally capture and compare s
- New Book Launched: Cosmeceuticals and Cosmetic Ingredientshttps://practicaldermatology.com/news/20141113-new_book_launched_cosmeceuticals_and_cosmetic_ingredients/2459067/"Cosmeceuticals and Cosmetic Ingredients" (McGraw Hill), the second textbook from Dr. Leslie Baumann, is now available through Amazon.com and booksellers internationally. Written for medical and skincare students and professionals, "Cosmeceuticals and Cosmetic Ingredients" focuses on the scien
- Oculus Innovative Sciences Commercializes Microcyn-Based Solution and Hydrogel for Treatment of Mild-to-Moderate Acne in Europehttps://practicaldermatology.com/news/20141113-oculus_innovative_sciences_commercializes_microcyn-based____solution_and_hydrogel_for_treatment_of_mild-to-moderate_acne_in_europe/2459068/Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care in 37 countries, today announced the European commercialization of Microcyn(R)-based GramaDerm(TM) Solution a
- A Pivotal Phase III Gevokizumab Study is Initiated in Patients With Pyoderma Gangrenosumhttps://practicaldermatology.com/news/20141104-a_pivotal_phase_3_gevokizumab_study_is_initiated_in_patients_with_pyoderma_gangrenosum/2459074/The Phase III gevokizumab study in patients with active pyoderma gangrenosum, a rare neutrophilic dermatosis of expanding necrotic skin ulcers, is open for patient enrollment. The objective of the study is to assess the efficacy and safety of gevokizumab in treating the active ulc
- Nerium International Announces Creation of Scientific Advisory Boardhttps://practicaldermatology.com/news/20141027-nerium_international_announces_creation_of_scientific_advisory_board/2459078/Nerium International established a Scientific Advisory Board, comprised of the following scientists and dermatologists: Dr. Adam Friedman, Dr. Neal Bhatia, Dr. Mira Stotland, Marie Bertrand, Dr. Debra J. Wattenberg, and Dr. Karthik Krishnamurthy. The mission of the
- SKINPACT Program Launched with New Global Awards Initiative to Support the Dermatology Communityhttps://practicaldermatology.com/news/20141010-skinpact_program_launched_with_new_global_awards_initiative_to_support_the_dermatology_community/2459088/Galderma, in partnership with the International League of Dermatological Societies, has started a search for initiatives that will fulfill an important role in strengthening the global dermatology community. Galderma launched a new global initiative un
- Peter Barton Hutt Appointed to Suneva Medical, Inc. Board Of Directorshttps://practicaldermatology.com/news/20141008-peter_barton_hutt_appointed_to_suneva_medical_inc_board_of_directors/2459093/Peter Barton Hutt was appointed a member of the Board of Directors of Suneva Medical, Inc., a privately-held aesthetics company. Mr. Hutt has specialized in food and drug law at the Washington, DC firm of Covington and Burling since 1960, pausing only to serve as Chief Counsel o
- Galderma Initiates US Study of Novel Muscle Relaxant for Aesthetic Dermatology and Cosmetic Surgeryhttps://practicaldermatology.com/news/20141006-galderma_initiates_us_study_of_novel_muscle_relaxant_for_aesthetic_dermatology_and_cosmetic_surgery/2459095/Galderma has initiated a Phase II clinical trial of a novel muscle relaxant in the US. The Phase II clinical trial is a multicenter, dose-ranging study designed to evaluate the safety and effectiveness of Galderma's internally developed liquid form of botulinum toxin for the tre
- Dermira Prices Initial Public Offeringhttps://practicaldermatology.com/news/20141003-dermira_prices_initial_public_offering/2459096/Dermira will price its initial public offering of 7,812,500 shares of common stock at a price to the public of 16 dollars per share. The shares are expected to begin trading on The NASDAQ Global Select Market on October 3, 2014 under the symbol DERM.Citigroup and Leerink Partners are acti
- Taclonex Granted New Indication for Scalp Plaque Psoriasis in Adolescent Patientshttps://practicaldermatology.com/news/20140930-combination_topical_treatment_approved_for_scalp_plaque_psoriasis_in_adolescent_patients/2459101/LEO Pharma Inc., has received a new indication for Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension for a topical combination treatment of plaque psoriasis of the scalp in patients 12 to 17 years. The new indication represents the first indication for adolescent patients a